Pre-Antiretroviral Therapy Serum Selenium Concentrations Predict WHO Stages 3, 4 or Death but not Virologic Failure Post-Antiretroviral Therapy. by Shivakoti, Rupak et al.
Nutrients 2014, 6, 5061-5078; doi:10.3390/nu6115061 
 
nutrients 
ISSN 2072-6643 
www.mdpi.com/journal/nutrients 
Article 
Pre-Antiretroviral Therapy Serum Selenium Concentrations 
Predict WHO Stages 3, 4 or Death but not Virologic Failure 
Post-Antiretroviral Therapy 
Rupak Shivakoti 1, Nikhil Gupte 1, Wei-Teng Yang 1, Noluthando Mwelase 2, Cecilia Kanyama 3, 
Alice M. Tang 4, Sandy Pillay 5, Wadzanai Samaneka 6, Cynthia Riviere 7, Sima Berendes 8,  
Javier R. Lama 9, Sandra W. Cardoso 10, Patcharaphan Sugandhavesa 11, Richard D. Semba 12, 
Parul Christian 13, Thomas B. Campbell 14 and Amita Gupta 1,* and the NWCS 319 and 
PEARLS study team 
1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, 
USA; E-Mails: rshivak1@jhmi.edu (R.S.); ngupte1@jhmi.edu (N.G.);  
weiteng.yang@gmail.com (W.-T.Y.) 
2 Department of Medicine, University of Witwatersrand, Johannesburg 2050, South Africa;  
E-Mail: tmwelase@witshealth.co.za 
3 University of North Carolina Lilongwe, Lilongwe, Private Bag A-104, Malawi;  
E-Mail: ckanyama@unclilongwe.org 
4 Department of Public Health and Community Medicine, Tufts University School of Medicine, 
Boston, MA 02111, USA; E-Mail: Alice.Tang@tufts.edu 
5 Durban International Clinical Research Site, Durban University of Technology, Durban 4001,  
South Africa; E-Mail: Pillay@ukzn.ac.za 
6 University of Zimbabwe Clinical Research Centre, Harare 999, Zimbabwe;  
E-Mail: wsamaneka@uzcrc.co.zw 
7 Les Centres GHESKIO, Port-Au-Prince, HT-6110, Haiti; E-Mail: criviere@gheskio.org 
8 International Public Health Department, Liverpool School of Tropical Medicine, Liverpool  
L3 5QA, UK; E-Mail: sima.berendes@googlemail.com 
9 Asociacion Civil Impacta Salud y Educacion, Lima, 4, Peru; E-Mail: jrlama@impactaperu.org  
10 STD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clinica Evandro Chagas, Fundacao 
Oswaldo Cruz, Rio de Janeiro 21045-900, Brazil; E-Mail: sandra.wagner@ipec.fiocruz.br 
11 Research Institute for Health Sciences, Chiang Mai 50200, Thailand;  
E-Mail: patcharaphan@rihes-cmu.org 
12 Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore,  
MD 21287, USA; E-Mail: rdsemba@jhmi.edu 
13 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, 
MD 21205, USA; E-Mail: pchrist1@jhu.edu 
  
OPEN ACCESS 
Nutrients 2014, 6 5062 
 
14 Department of Medicine, Division of Infectious Diseases, University of Colorado School of 
Medicine, Aurora, CO 80045, USA; E-Mail: Thomas.Campbell@ucdenver.edu 
* Author to whom correspondence should be addressed; E-Mail: agupta25@jhmi.edu;  
Tel.: +1-410-502-7696; Fax: +1-443-287-6440. 
Received: 28 July 2014; in revised form: 13 September 2014 / Accepted: 15 October 2014 /  
Published: 13 November 2014 
 
Abstract: A case-cohort study, within a multi-country trial of antiretroviral therapy (ART) 
efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS)), 
was conducted to determine if pre-ART serum selenium deficiency is independently 
associated with human immunodeficiency virus (HIV) disease progression after ART 
initiation. Cases were HIV-1 infected adults with either clinical failure (incident World 
Health Organization (WHO) stage 3, 4 or death by 96 weeks) or virologic failure by  
24 months. Risk factors for serum selenium deficiency (<85 μg/L) pre-ART and its 
association with outcomes were examined. Median serum selenium concentration was  
82.04 μg/L (Interquartile range (IQR): 57.28–99.89) and serum selenium deficiency was 
53%, varying widely by country from 0% to 100%. In multivariable models, risk factors for 
serum selenium deficiency were country, previous tuberculosis, anemia, and elevated  
C-reactive protein. Serum selenium deficiency was not associated with either clinical failure 
or virologic failure in multivariable models. However, relative to people in the third quartile 
(74.86–95.10 μg/L) of serum selenium, we observed increased hazards (adjusted hazards 
ratio (HR): 3.50; 95% confidence intervals (CI): 1.30–9.42) of clinical failure but not 
virologic failure for people in the highest quartile. If future studies confirm this relationship 
of high serum selenium with increased clinical failure, a cautious approach to selenium 
supplementation might be needed, especially in HIV-infected populations with sufficient or 
unknown levels of selenium. 
Keywords: HIV; selenium; antiretroviral therapy; nutrition; treatment failure; cohort studies 
 
1. Introduction 
There are around 35 million people living with Human immunodeficiency virus (HIV) infection in 
both developing and developed countries [1]. Access to antiretroviral therapy (ART), which can control 
but not cure the infection, has increased 30-fold since 2003 [1]. As treatment needs to continue for life 
and the number of people on ART is expected to rise further, with 7.1 million still lacking access to  
ART [1], it is important to understand ways to maximize treatment efficacy. Clinical treatment failure 
(World Health Organization (WHO) defined stage 3, 4 or death) and virologic treatment failure have 
been attributed to a variety of causes including malnutrition and micronutrient deficiencies [2–4]. Serum 
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selenium deficiency has been associated with higher morbidity and mortality among ART-naïve  
HIV-infected people in multiple studies but there is mixed data to date on whether selenium 
supplementation has benefits in HIV population [5–10]. Whether selenium deficiency is associated with 
adverse treatment outcomes in the era of ART remains unanswered. In addition, selenium has a U-shaped 
link with other health outcomes including cancer and all-cause mortality [11], but whether or not that is 
relevant to HIV outcomes post-ART initiation is not known. 
Selenium is an essential micronutrient and an essential component of the selenocysteine amino  
acid that is incorporated into 25 different selenoproteins [12]. Most of the well-studied selenoproteins, 
such as glutathione peroxidase (Gpx) and thioredoxin reductase (Txnrd), are antioxidants while other 
selenoproteins regulate metabolism or tissue development [13]. Antioxidants, such as selenoproteins, can 
counteract the oxidative stress and subsequent damage to DNA, proteins and lipids caused by pro-oxidants. 
This is important in the context of HIV infection as oxidative stress is increased during both HIV infection 
and ART treatment [14]. In addition, the selenoproteins Gpx and Txnrd1 have been shown to be important 
during HIV infection by decreasing viral activation and negatively regulating the HIV Tat protein, 
respectively [15,16]. 
Selenium concentration varies by geography [17] and has a bi-directional relationship with inflammation 
and the acute phase response [11,18]. Low concentrations of selenium have been linked with disorder of 
various tissues and diseases [11]. However, higher concentrations of selenium can also be detrimental 
as seen in US populations where a non-linear U-shaped relationship with cancer and all-cause mortality 
has been observed [11]. Studies to date in HIV-infected adults have not assessed the association between 
serum selenium deficiency pre-ART and clinical outcomes post-ART, while many pre-ART era studies 
did not adjust for inflammation and other confounders [11,19]. 
The objective of our study was to assess the risk factors for serum selenium deficiency pre-ART (baseline) 
and to determine if baseline serum selenium deficiency was independently associated with treatment 
outcomes after controlling for potential confounders including inflammation. To address these questions, 
we conducted a case-cohort study of ART naïve HIV-infected patients who initiated ART in the 
“Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS)” trial [20]. Based on 
existing literature of HIV-infected ART-naïve individuals, we hypothesized that pre-ART serum selenium 
deficiency would be associated with greater treatment failure. Interestingly, we find that high levels of 
serum selenium concentrations, more so than serum selenium deficiency, were associated with adverse 
treatment outcomes and our results could have implications for selenium supplementation studies. 
2. Methods 
2.1. Study Population 
We performed a nested case-cohort study within the PEARLS trial [20], a randomized clinical trial of 
the AIDS Clinical Trial Group (ACTG A5175, clinicaltrials.gov NCT00084136). 1571 HIV-1 infected 
adults (≥18 years old) with CD4+ T cell count less than 300 cells/mm3 were enrolled and followed between 
May 2005 and May 2010. Participants were randomly allocated with equal probability to one of three 
different ART regimens: (A) efavirenz plus twice-daily lamivudine-zidovudine; (B) atazanavir plus 
didanosine EC and emtricitabine all given once daily; (C) and efarivenz plus emtricitabine-tenoforvir-
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DF once daily. Participants were from nine different countries: Brazil (n = 231), Haiti (n = 100), India 
(n = 255), Malawi (n = 221), Peru (n = 134), South Africa (n = 210), Thailand (n = 100), United States 
(n = 210) and Zimbabwe (n = 110). Participants who were pregnant or had an acute illness or other 
comorbidities, as described in detail elsewhere [20], were excluded from the study. 
We selected the case-cohort design for this study as this allows for prevalence estimation and assessment 
of multiple outcomes [21,22]. The case-cohort was composed of a random subcohort of 270 participants 
along with the remaining cases in PEARLS that were not sampled as part of the subcohort (Figure 1). 
Cases were defined as either primary treatment failure or secondary treatment failure. Primary case 
outcome for this study was clinical treatment failure (incident WHO stage 3, 4 or death), and secondary 
case outcome was virologic failure (HIV-1 RNA levels ≥1000 copies/mL for two successive visits at 
≥16 weeks after study entry). The random subcohort was selected by stratified random sampling with 
30 participants from each of the nine countries. The total number of people in the case-cohort was 
dependent on whether the outcome of interest was primary (treatment failure, n = 470), or secondary 
(virologic failure, n = 411) (Figure 1). 
2.2. Ethics Statement 
Institutional review board and ethics committees at each participating institution and the Johns Hopkins 
University School of Medicine granted approval for this study. Appropriate guidelines from the United 
States Department of Health and Human Services for human experimentation were followed and 
participants granted written informed consent for the study. 
2.3. Data Collection and Laboratory Analysis 
Clinical history was measured at entry (pre-ART) and at weeks 2, 4, 8 and every four weeks after that 
through week 24, and every eight weeks through week 96. Diagnostic criteria were standardized across 
the different clinical sites. Body mass index (BMI) was measured at baseline and serum was collected 
at baseline and stored at −80 °C. Plasma HIV-1 viral load was assessed using Roche Amplicor Monitor 
Assay (v1.5, Roche Molecular Diagnostics, Branchburg, NJ, USA). Baseline serum selenium 
concentration was measured using a Perkin-Elmer Analyst 600 graphite furnace atomic absorption 
spectrometer at Johns Hopkins University and were run in batches. Serum selenium deficiency was 
defined as serum concentrations of <85 μg /L based on previous studies of HIV and selenium [23–25].  
C-reactive protein (CRP) was measured using an enzyme-linked immunosorbent assay (ELISA) kit  
(R & D Systems). Serum albumin, hemoglobin and CD4 cell counts were also assessed at site 
laboratories that were all externally quality assured as part of the National Institute of Health (NIH) 
Division of AIDS and ACTG Network lab quality assurance [20]. 
  
 
Nutrients 2014, 6 5065 
 
Figure 1. Case-cohort design for primary clinical treatment failure and secondary virologic 
failure. The case-cohort analysis consisted of the random sub-cohort (random subsample 
from full cohort) and any additional cases from the full cohort that met the outcome 
definition. Our primary outcome (1°) was defined as incident WHO stage 3 or 4 event or 
death (n = 234 controls and n = 236 cases, total N = 470) within 96 weeks post-ART initiation. 
Secondary outcomes was virologic failure (VF) (n = 246 controls and n = 165 cases, total  
N = 411), defined as 2 successive plasma HIV-1 RNA levels >1000 copies/mL at or after  
16 weeks post-ART initiation. The subcohort was used to determine prevalence and 
characteristics associated with serum selenium deficiency. The full-case cohort (analysis 
data) was used to study the association of baseline serum selenium concentrations with 
treatment outcome. 
 
2.4. Statistical Analysis 
The random subcohort was used for prevalence estimates of baseline serum selenium deficiency by 
various baseline characteristics. Differences in serum selenium deficiency prevalence by covariates were 
tested using the Wilcoxon’s rank sum test for continuous variables and Fisher’s exact test for categorical 
variables. CRP and viral load variables were log-transformed. Odds ratios (OR) and 95% confidence 
intervals (CI) of serum selenium deficiency at baseline were estimated by covariates using univariable 
and multivariable logistic regression. Age, gender and albumin were forced in multivariable models due 
to evidence of association with selenium in past studies [19,26] and also because they had a trend of 
association (p < 0.1) in univariable models. BMI was forced in the model to control for malnutrition. 
Associations between outcomes and serum selenium concentrations adjusting for other covariates were 
estimated for the full case-cohort using univariable and multivariable Cox proportional hazard models 
stratified by treatment and country for clinical failure and by country for virologic failure. Stratifying by 
treatment in addition to country for virologic failure models did not change the results (data not shown). 
Barlow weighting [21] and robust standard errors were used in the Cox models to account for the stratified 
design of the study. 
 
Nutrients 2014, 6 5066 
 
Selenium was categorized as either normal or selenium deficient based on serum cutoffs (<85 μg/L) 
or as quartiles of serum selenium for univariable and multivariable analyses of clinical treatment failure 
and virologic failure. Multivariable model 1 was used to determine association of selenium status (binary 
or quartile) with clinical failure after adjusting for gender, age, BMI, CD4 count, viral load, hemoglobin 
and albumin while multivariable model 2 also adjusted for inflammation (CRP). Multivariable model 3 
was used to determined association of selenium status with virologic failure after adjusting for gender, 
age, BMI, CD4 count, viral load, treatment arm while multivariable model 4 also adjusted for CRP. Further 
adjusting for albumin and hemoglobin in model 3 and 4 did not affect the results and a simpler model is 
presented given that previous studies do not usually include these variables in virologic failure models. 
Race was collinear with country and was not included in multivariable models. STATA version 13 (Stata 
Corp, College Station, TX, USA) and S-plus Tibco Spotfire version 7.2 (TIBCO, Palo Alto, CA, USA) 
were used for data analysis. Forest plots were created using GraphPad Prism Software version 5 
(GraphPad software Inc., La Jolla, CA, USA). 
3. Results 
3.1. Description of Study Population 
As shown in Figure 1, the primary (clinical treatment failure as outcome) case-cohort comprised of  
470 individuals with 234 controls and 236 cases. The secondary (virologic failure as outcome)  
case-cohort comprised of 411 individuals with 246 controls and 165 cases. Serum selenium 
concentrations were available for 88% (n = 413) of primary case-cohort and 93% (n = 381) of the 
secondary case-cohort participants. There were no differences in the characteristics (age, gender, BMI) 
of participants with missing selenium concentrations compared to the participants with available ones. 
The majority of missing data, 78% of primary case-cohort and 52% of secondary case-cohort, were 
samples from India, which could not be assayed due to regulatory difficulties with exporting samples. 
3.2. Risk Factors for Baseline Serum Selenium Deficiency 
Median pre-ART (baseline) serum selenium concentrations in the subcohort was 82 μg/L (IQR: 57–100) 
and the levels varied widely by country. The prevalence of serum selenium deficiency, as defined as serum 
concentrations of <85 μg/L, was 53%. Gender (p = 0.02), country (p < 0.001), race (p = 0.007), prior 
tuberculosis (TB) (p < 0.001), hemoglobin (p = 0.008), albumin (p < 0.0001) and log10 CRP (p = 0.006) 
were significant risk factors for baseline serum selenium deficiency (Table 1). Females were more likely 
to be deficient than males (OR: 1.86, 95% CI: 1.13–3.08). Prevalence of deficiency varied widely 
between countries ranging from 0% (US) to 100% (Zimbabwe) and relative to Haiti (with 7% deficiency) 
persons from Malawi, Brazil, and South Africa had the highest odds of being selenium deficient  
(Figure 2). Anemia (OR: 1.89, 95% CI: 3.11–1.14), lower concentrations of albumin (OR: 4.46, 95% CI: 
2.52–7.86), and higher levels of log10 CRP (OR: 1.79, 95% CI: 1.20–2.65) were also associated with 
greater serum selenium deficiency. 
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Table 1. Characteristics of study population by serum selenium deficiency (<85 μg/L) status. 
Characteristic 
 Selenium Levels 
p-Value 
All (n = 252)  
n (%) 
All (n = 252)  
Median (IQR) 
Deficient (n = 134) 
n (%) 
Normal (n = 118)  
n (%) 
Gender      
Male  131 (52) 88 (58–107) 60 (46) 71 (54) 0.02 
Female 121 (48) 78 (57–95) 74 (61) 47 (39)  
Age, median (IQR)  35 (30–41)  35 (30–41) 34.5 (29–41) 0.26 
Country      
Brazil 30 (12) 53 (46–61) 26 (87) 4 (13) <0.001 
Haiti 30 (12) 109 (99–126) 2 (7) 28 (93)  
India 18 (7) 88 (67–106) 8 (44) 10 (56)  
Malawi 30 (12) 58 (49–73) 28 (93) 2 (7)  
Peru 29 (12) 92 (83–101) 10 (34) 19 (66)  
South Africa 29 (12) 73 (67–84) 22 (76) 7 (24)  
Thailand 27 (11) 93 (84–97) 9 (33) 18 (67)  
US 30 (12) 118 (108–128) 0 (0) 30 (100)  
Zimbabwe  29 (12) 50 (41–59) 29 (100) 0 (0)  
Race      
White 15 (6) 103 (46–125) 7 (47) 8 (53) 0.007 
Black 133 (53) 73 (54–99) 84 (63) 49 (37)  
Hispanic 57 (23) 87 (67–101) 26 (46) 31 (54)  
Asian 46 (18) 91 (79–97) 17 (37) 29 (63)  
Body mass index (kg/m2)      
<18.5  19 (8) 63 (45–97) 13 (68) 6 (32) 0.16 
18.5–25 166 (66) 83 (57–99) 91 (55) 75 (45)  
≥25 67 (27) 88 (67–108) 30 (45) 37 (55)  
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Table 1. Cont. 
Characteristic 
 Selenium Levels 
p-Value 
All (n = 252)  
n (%) 
All (n = 252)  
Median (IQR) 
Deficient (n = 134) 
n (%) 
Normal (n = 118)  
n (%) 
Treatment      
A 94 (37) 84 (57–96) 48 (51) 46 (49) 0.61 
B 83 (33) 76 (58–100) 48 (58) 35 (42)  
C 75 (30) 85 (59–104) 38 (51) 37 (49)  
Prior TB diagnosis 45 (18) 84 (57–96) 45 (18) 35 (78) <0.001 
CD4 count, median (IQR), cells/μL  179 (88, 231)  179 (88, 231) 171 (71, 233) 0.53 
Viral load, median (IQR), log10 copies/mL 5.1 (4.6, 5.5)  5.1 (4.7, 5.5) 5.0 (4.5, 5.5) 0.26 
Hemoglobin, median (IQR), g/dL  12.4 (10.9, 13.8)  12.1 (10.6, 13.7) 12.8 (11.4, 14.1) 0.008 
Albumin, median (IQR), g/dL 3.9 (3.6, 4.3)  3.8 (3.3, 4.1) 4.1 (3.9, 4.4) <0.0001 
Log CRP, median (IQR), mg/L 3.4 (1.4, 10.3)  5.0 (1.4, 16.2) 2.4 (1.2, 7.1) 0.006 
Data are presented from the random subcohort (n = 252 with selenium data). The first column gives the total number (%) of people in the subcohort within each category of 
a covariate; the second column gives median serum selenium concentration by covariates; in the third and fourth column, data are represented as number (%) of people in 
the subcohort that are either selenium deficient or normal within each category of a covariate. For continuous covariates, the median and interquartile range (IQR) values of 
the covariate is presented for selenium deficient and normal; Wilcoxon’s rank sum test for continuous variables and Fisher’s exact test for categorical variables were used 
to calculate the p-values shown in the last column to compare those with and without serum selenium deficiency in the subcohort. Units for serum selenium concentration 
is μg/L and serum selenium deficiency is defined as <85 μg/L. Abbreviations: IQR: Interquartile range; OR: Odds Ratio; CI: confidence intervals; CRP:  
C-reactive protein. Treatments A: efavirenz plus twice-daily lamivudine-zidovudine; B: atazanavir plus didanosine EC and emtricitabine all given once daily; C: efarivenz 
plus emtricitabine-tenoforvir-DF once daily. 
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After adjusting for sex, age, BMI and albumin, independent risk factors for selenium deficiency were 
country, previous TB (adjusted odds ratio (aOR): 9.79, 95% CI: 1.69–56.83), anemia (aOR: 3.38, 95% 
CI: 1.27–8.99) and log10 CRP (aOR: 3.42, 95% CI: 1.60–7.29) in multivariable logistic regression 
models (Figure 2). Being from Malawi, Brazil and South Africa also had the highest odds of being 
deficient relative to Haiti in multivariable models (Figure 2). Adjusted OR could not be calculated for 
Zimbabwe as everyone was deficient and for the US as no one was deficient. 
Figure 2. Independent factors associated with serum selenium deficiency. Forest plot 
showing the odds ratio (OR) of being selenium deficient (based on serum cutoffs) by 
covariates. Univariable and multivariable logistic regression were used to calculate the OR of 
being selenium deficient. Variables included in the model were selenium, gender, age, body 
mass index (BMI), country, prior Tuberculosis (TB), anemia, albumin and log C-reactive 
protein (CRP). Reference groups for categorical variables were male for gender, Haiti for 
country, no anemia and no prior TB. Zimbabwe and USA are excluded due to everyone and 
no one being deficient, respectively. 
 
3.3. Association of Baseline Serum Selenium with Clinical Failure and Virologic Failure 
There were 193 cases (46.7%) in the full case-cohort that had clinical treatment failure defined as 
WHO stage 3 (n = 129 including 45 pulmonary TB), 4 (n = 49 including 13 extrapulmonary TB) or death 
(n = 15). Serum selenium deficiency (<85 μg/L) was not associated with increased hazards (hazard ratio 
(HR): 1.85, 95% CI: 0.92–3.7) of clinical treatment failure in univariable analyses (Table 2a). In 
multivariable model adjusting for gender, age, BMI, CD4 count, viral load, hemoglobin and albumin 
(Multivariable model 1), serum selenium deficiency was not associated (aHR: 1.43, 95% CI: 0.68–3.02) 
with clinical failure either (Table 2a). Further adjusting for inflammation (CRP) (Multivariable model 2) 
did not change the lack of association (aHR: 1.14, 95% CI: 0.49–2.61) between serum selenium deficiency 
and clinical failure (Table 2a). 
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Table 2. (a) Association of baseline serum selenium concentrations with clinical treatment failure (n = 413); (b) Association of baseline serum 
selenium concentrations with virologic failure (n = 381). Univariable and multivariable cox proportional hazards regression models were used 
to calculate the hazard ratios to assess the association of serum selenium with clinical treatment failure (a) and virologic failure (b) in the full 
case-cohort. The outcome of interest was clinical failure (primary outcome) or virologic failure (secondary outcome). For the univariable and 
multivariable analyses of clinical failure and virologic failure, serum selenium was categorized as either a binary variable (deficient or not) or 
as quartiles with the third quartile as the reference. 
a 
 n (%) Univariable 
Multivariable 1 (Adjusted for Gender, Age, BMI, 
CD4 Count, Viral Load, Hemoglobin and Albumin) 
Multivariable 2 (Adjusted for Variables 
in Multivariable Model 1 + CRP) 
By selenium deficiency status     
Normal (≥85 μg/L) 173 (42) Reference Reference Reference 
Selenium Deficient (<85 μg/L) 240 (58) 1.85 (0.92–3.70) 1.43 (0.68–3.02) 1.14 (0.49–2.61) 
By quartiles of selenium     
Quartile 1 (<55.60 μg/L) 98 (24) 3.51 (1.06–11.60) 2.71 (0.70–10.45) 2.25 (0.57–8.79) 
Quartile 2 (55.60–75.52 μg/L) 94 (23) 2.57 (1.04–6.35) 1.74 (0.60–5.03) 1.46 (0.49–4.35) 
Quartile 3 (75.52–97.45 μg/L) 111 (27) Reference Reference Reference 
Quartile 4 (>97.45 μg/L) 110 (26) 2.16 (0.88–5.30) 3.50 (1.30–9.42) 4.13 (1.65–10.35) 
b 
 n (%) Univariable 
Multivariable 3 (Adjusted for Gender, Age, BMI, 
CD4 Count, Viral Load, Treatment Arm) 
Multivariable 4 (Adjusted for Variables 
in Multivariable Model 3 + CRP) 
By selenium deficiency status     
Normal (≥85 μg/L) 221 (58) Reference Reference Reference 
Selenium Deficient (<85 μg/L) 160 (42) 0.88 (0.43–1.8) 0.68 (0.31–1.48) 0.64 (0.28–1.46) 
By quartiles of selenium     
Quartile 1 (<55.73 μg/L) 89 (23) 1.37 (0.47–3.98) 1.32 (0.45–3.91) 1.29 (0.44–3.79) 
Quartile 2 (55.73–74.86 μg/L) 85 (23) 1.11 (0.50–2.51) 0.97 (0.43–2.22) 0.91 (0.39–2.13) 
Quartile 3 (74.86–95.10 μg/L) 99 (26) Reference Reference Reference 
Quartile 4 (>95.10 μg/L) 108 (28) 0.84 (0.31–2.33) 0.92 (0.34–2.50) 0.87 (0.30–2.49) 
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Interestingly, we observed that when serum selenium quartiles were used as the exposure variable (with 
quartile 3 as the reference) in univariable models, the lowest quartile (HR: 3.51, 95% CI: 1.06–11.60) and 
quartile 2 (HR: 2.57, 95% CI: 1.04–6.35) were associated with clinical treatment failure while there was 
a trend for association with the highest quartile (HR: 2.16, 95% CI: 0.88–5.30) (Table 2a). In multivariable 
model 1, there was also an increased hazards for the lowest quartile (aHR: 2.71, 95% CI: 0.70–10.45) and 
quartile 2 (aHR: 1.74, 95% CI: 0.60–5.03) relative to quartile 3, but this association was not statistically 
significant (Table 2a). However, the highest quartile had a statistically significant hazards (aHR: 3.50, 
95% CI: 1.30–9.42) (Table 2a) of clinical failure. This association of the highest quartile (relative to 
third quartile) of serum selenium with clinical failure remained even after adjusting for CRP 
(multivariable model 2 in Table 2a) as well as after adjusting for other antioxidants (retinol and Vitamin 
E) (data not shown). Given that clinical features of WHO stage III and death (both defined as clinical 
failure here along with WHO stage IV) are quite different, we tested and confirmed the association of 
highest quartile of selenium with outcome (aHR: 3.47, 95% CI: 1.41–8.52) even when we limited our 
clinical failure definition to WHO stage III and IV (excluding death). People from Haiti, India and USA 
were more likely to be in the highest quartile of serum selenium (data not shown) and accounted for 
most (98%) of the cases in the highest quartile. 
To determine the association of baseline serum selenium concentrations and virologic failure, we also 
categorized selenium as either a binary variable or as quartiles. Neither serum selenium deficiency nor 
any of the serum selenium quartiles were associated with virologic failure in univariable or multivariable 
models (Table 2b). 
4. Discussion 
In our multicenter study, prevalence of serum selenium deficiency varied significantly among  
HIV-infected people residing in diverse regions of the world. Baseline serum selenium deficiency  
pre-ART was associated with country of origin, anemia, CRP concentrations, and previous TB.  
Pre-ART serum selenium deficiency was not associated with clinical or virologic treatment failure. 
Interestingly, we observed that serum selenium concentrations in the highest quartile were predictive of 
increased clinical failure compared to people in the third quartile. While other studies have shown that 
selenium deficiency is associated with natural HIV disease progression and severity in the pre-ART era, 
our study is the first to show that high baseline serum selenium concentrations among HIV-infected people 
initiating ART is associated with the adverse treatment outcome of clinical failure. Our findings have 
important implications for programs considering selenium supplementation strategies among  
HIV-infected adults initiating ART. 
We found that the prevalence of serum selenium deficiency varied greatly between countries, ranging 
from 0% to 100%. Unlike many other micronutrients, selenium levels in humans do not necessarily 
correlate with malnutrition [11] (and as seen with the lack of association with BMI in our study) but 
rather on the differences in the content of selenium in the soil, the varying bioavailability of selenium in 
diverse foods, use of micronutrient supplements and the access to imported food from other regions of 
the world [17,27]. 
Other risk factors for baseline serum selenium deficiency were anemia, higher CRP concentrations and 
prior TB. Low serum selenium has previously been associated with anemia and potential biological 
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mechanisms include low selenium affecting inflammation to cause anemia of inflammation or low 
selenium increasing oxidative stress that leads to erythrocyte damage [28]. The inverse association of CRP 
with serum selenium levels in our study has also been observed by other groups in both non-HIV [26,29,30] 
and HIV settings [19,31]. However, as selenium and inflammation have a bi-directional relationship [11,18], 
it is possible that CRP might not be a risk factor but a result of selenium deficiency as deficiency can also 
lead to changes in inflammation. Individuals with replete selenium could potentially control inflammation 
and the acute phase response (hence CRP) by inhibiting NF-κβ signaling [26]. 
Previous cross-sectional and longitudinal HIV natural history studies in the pre-ART era have shown 
an association between low serum selenium concentrations and progression of infection, morbidity and 
mortality [19,32–37]. Low serum selenium concentration has also been associated with HIV progression 
among persons already on ART but studies assessing baseline selenium status and post-ART initiation 
outcomes have been lacking [23,24,38–46]. In two randomized controlled trials (RCT) of HIV-positive 
people in the US, selenium supplementation reduced viral load and hospitalizations but in these studies 
no one had selenium deficiency and the majority of people were already on ART [8,9]. In a third RCT 
of selenium supplementation of HIV-positive pregnant women (only ~2% were selenium deficient) in 
Tanzania where minimal beneficial effects of supplementation on CD4 count, viral load and mortality were 
seen, the vast majority of participants (4%) did not receive ART during the study [7]. To our knowledge, 
this is the first study to longitudinally follow HIV-positive patients initiating ART to study the association 
of baseline pre-ART serum selenium concentrations with progression to clinical treatment failure post-ART. 
We did not observe serum selenium deficiency to be associated with clinical treatment failure. 
However, we observed an increased clinical failure in people with the highest quartile of serum selenium 
concentrations. While this was initially surprising as our hypothesis was that more failure would be 
observed in people with selenium deficiency, the result we found is biologically plausible. A U-shaped 
relationship has been observed where both high and low selenium status have been associated with all-cause 
mortality and cancer in US populations [11]. This is consistent with the idea that a narrow range of therapeutic 
benefit exists for many micronutrients [47] and that too much selenium might result in adverse outcomes. 
Importantly, this association was observed even after controlling for CRP because it has been suggested 
that not adjusting for acute phase response (example: CRP) has been one of the weaknesses of studies 
looking at selenium and HIV disease outcomes [11,19]. Whether inflammation is a confounder or a result 
of selenium deficiency, the association of high serum selenium with clinical failure remains the same. 
The potential adverse role of elevated selenium could be explained by looking at the role of selenium 
as a component of many antioxidants. While pro-oxidants are often thought of as harmful and antioxidants 
as beneficial, it is crucial to understand that both of them serve important biological functions and a balance 
between pro-oxidants and antioxidants is necessary [48]. When there is an imbalance with an excess of 
pro-oxidants, damage can be done to crucial cellular macromolecules including DNA, RNA and  
proteins [49]. However, a lack of pro-oxidants and an excess of antioxidants could adversely affect necessary 
functions such as cell death, inflammation and aging [48]. As oxidative stress is increased during both HIV 
infection as well as ART [14], it is possible that for people with high selenium, there is a dysregulation of 
oxidative stress resulting in worse treatment outcomes. Importantly, this association of elevated  
serum selenium with clinical failure did not change even after controlling for vitamin A and vitamin E  
(other antioxidants). 
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Based on our quartile values, the group with the highest hazards of clinical failure were people with 
baseline serum selenium concentrations of greater than 97 μg/L while the group with the lowest hazards 
were people with concentrations between 75 and 97 μg/L. A potential reason that high serum selenium, 
but not serum selenium deficiency (<85 μg/L), was associated with greater failure might be because 
there are different ranges for selenium needed for optimal expression of different selenoproteins [50,51]. 
Thus, it could be possible that too much activity (seen at high levels) of a certain selenoprotein important 
during HIV and ART might result in dysregulation of oxidative stress and worse treatment outcomes. 
Lastly, we did not find any association between selenium deficiency and virologic failure similar to 
a recent study conducted in Thailand but in contrast to a selenium supplementation trial conducted in the 
US, which had adults predominantly on ART and without evidence of selenium deficiency [8,52]. The 
results of the US RCT study, however, were controversial [53–55] due to potential issues with study 
design and interpretation of results. A new trial by the same group in Botswana [10] showed that the viral 
load was not different (although CD4 levels were) in ART-naïve HIV-infected people after concurrent 
supplementation with multivitamins (defined as Vitamin B, C and E) and selenium as compared to placebo, 
multivitamins alone or selenium alone. The discordant findings between the association of selenium with 
clinical failure as compared to virologic failure could potentially be that selenium causes clinical failure 
through other mechanisms such as chronic inflammation or dysregulation of oxidation reactions without 
affecting the viral load. 
Our study did have some limitations. While we were able to estimate country specific selenium 
deficiency prevalence and observed some substantial differences by country, we were not sufficiently 
powered to look at the independent effects of individual country and selenium interactions on clinical or 
virological outcomes. However, this study still gives us valuable biological information on serum selenium 
concentrations (irrespective of country) and response to treatment. Another limitation of our study is that 
serum selenium concentrations, while widely used to define deficiency in previous HIV studies, might not 
reflect true selenium status of the whole body as well as at a cellular level (as glutathione peroxidase would 
have). We also did not account for social factors in our study including substance abuse and criminalization 
that can affect treatment failure, however these factors usually affect treatment adherence and are likely 
not as important to our study as the patients had relatively high treatment adherence [56]. Finally, the 
association we observe cannot determine causality. However, we provide valuable information for future 
studies and randomized trials on the potentially narrow therapeutic range of selenium and probable need 
for different recommendations by country or selenium status in the population. 
5. Conclusions 
In conclusion, high concentrations of serum selenium pre-ART was associated with increased clinical 
failure in our multi-country study. Supplementation of selenium for HIV-infected people initiating ART 
should be handled with caution, as we need further studies in diverse settings to determine the range of 
selenium in the population and the effect of low or high selenium on ART outcomes. 
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